85.7 F
San Fernando
Friday, Mar 29, 2024
Array

Valley Firm Develops COVID Test for Transplant Patients

One Lambda, a West Hills subsidiary of Thermo Fisher Scientific of Massachusetts, has developed a new COVID-19 test specifically for organ transplant candidates and recipients. Called the LABScreen COVID Plus Assay, the test will detect COVID-19 antibodies in the body more accurately by using software developed by Texas company Luminex. Laboratories at Emory University, Stanford University, University of Cincinnati and the University Health Network in Toronto contributed to test development. The West Hills location has been developing, manufacturing and storing chemical substances, instruments and software related to transplant diagnostics for a year now, the Massachusetts life science giant said. “Transplant patients have unique needs compared to other COVID-19 patients, and with the support of Luminex and our research partners, we’re delivering an innovative solution that’s tailored to meet those needs,” Nicole Brockway, president of the transplant diagnostic division for Thermo Fisher, said in a statement. “We believe (Thermo Fisher’s) expertise with antibody assay development and commitment to the transplant community is critical to develop an assay for transplant patients that could both detect neutralizing antibodies and rule out false positives,” added Dr. Howard Gebel, co-director of the Emory University Hospital HLA laboratory. The test is currently available for research and emergency use only, Thermo said.

Featured Articles

Related Articles